Our Approach to Cancer Care is Like No Other

XCancer, formerly The Urology Cancer Center (UCC) &  XCancer Omaha, formerly GU Research Network, were founded in 2010 by Dr. Luke Nordquist, and rapidly rose to the highest ranks as an elite center in the U.S. for the treatment and innovative research for Prostate & Urologic Cancers (Kidney, Bladder, Testicular). Patients from more than 42 states, internationally, and patients referred from major centers such as Mayo Clinic, Johns Hopkins, and Memorial Sloan Kettering all call XCancer home for their care.

HOW DID WE GET HERE?

With degrees in both Pharmacy and Medicine from Creighton University, Dr. Luke completed his Internal Medicine training at the H. Lee Moffit Cancer Center in Tampa, FL & Oncology training at Memorial Sloan Kettering Cancer Center in NYC. His interest and dedicated research were in the field of Prostate Cancer and Immune Therapies.

In 2010, Dr. Luke opened XCancer with the sole purpose of creating a highly focused, highly compassionate, and highly cutting-edge cancer center dedicated only to Prostate & Urologic cancers.

He started in 2010 with 3 staff and 3 research clinical trials. Over ten years later, he has over 50 employees and has been an investigator on several hundred prostate & urologic cancers clinical trials which has led to the FDA approval of many life-saving treatments. XCancer has performed several first-in-the-world treatments on early-phase clinical trials and is considered a top site to perform the latest research for pharmaceutical companies that have novel cancer therapies. XCancer is often asked by major centers such as Duke, Cornell, and Sloan Kettering to partner in clinical trials because of our reputation for patient experience, patient volumes, and quality of work.

What Makes Us Different?

  • You will quickly notice when you drive up to XCancer and walk inside that this center and its people are like no other. The center was designed to feel cutting-edge yet give you a sense of comfort during your experience. We replaced the sterile cold feeling of most medical clinics with warm features, natural and indirect lighting, and other comforts of home such as coffee from a mug and homemade cookies (healthy snacks also). We literally have patients stop by on their days off of therapy just to sit and have a cup of coffee.

  • You will clearly sense that every staff member you come into contact with is there for you. They are all hand-picked for their knowledge and personality. They have positive attitudes and do everything they can to help lift your burdens.

  • All too often patients spend hours waiting to be put in a room then wait longer for the clinical team to see them. That is unacceptable to us. We continuously learn from a patient's prior visits and more accurately know how long each future visit will likely take and schedule accordingly to stay on time. We know that patients with advanced cancer may need more time. They may have scans to review, treatment changes, or discuss end-of-life issues. This may take significantly longer and we don't want to rush such important conversations. By more accurately predicting appointment times we continuously strive to minimize patient wait times allowing more time to spend with each patient.

  • Dr. Luke feels strongly about the importance of educating each patient and their caregiver(s) to a level they understand. It is not uncommon for him to spend 2-3 hours with each new patient. No matter how simple and straightforward your case is or how complex, he will discuss everything thoroughly. He educates patients on what a cancer is, generally speaking, and provides extensive but simple-to-understand details about their specific type of cancer. After new patients and their families understand that, he will address their cancer situation and what all of their treatment options are including standards of care, clinical research trials, compassionate options, and "outside the box" considerations. He promises every patient that all of their questions will be answered by the time they leave and just in case they forget a question, they are all given his cell phone number and email.

  • Patients will experience the true team approach. During your visit with Dr. Luke, he is accompanied by a Nurse Practitioner (NP) and often a research coordinator or other staff. During the visit, the staff are relaying orders electronically and communicating with other office staff so when Dr. Luke or his NP are done with your appointment, your treatments, referrals, prescriptions, next appointments, and scans have already all been addressed. If you are an out of town patient, labs and radiology imaging can be completed right in our office with results the same day.

  • Patients at other cancer centers are required to call an answering service after hours and on weekends and they may end up speaking with a nurse or another physician covering for their doctor. At XCancer every patient and caregiver(s) is given Dr. Luke's cell phone number and are encouraged to call and speak with him directly 24/7. If Dr. Luke is unavailable, his NPs who have also been part of your visits will cover his calls.

  • One of the biggest issues for cancer patients today is the high cost of care. Medical bankruptcy is the number one cause of bankruptcy in the U.S. today. XCancer's Financial Team works tirelessly for our patients to avoid patient financial strains. They utilize patient foundations and pharmaceutical companies directly often to get free drug when it could otherwise cost tens of thousands of dollars a dose. Each year the Financial Team brings in several millions of dollars of free drug for XCancer patients. Also by placing patients on clinical trials, otherwise expensive treatments are provided at no charge to patients. Dr. Luke wants every patient to receive the right care regardless of their insurance, lack of insurance or inability to pay.

Why XCancer For Your Expert Second Opinion?

  • As an example, for non-curable prostate cancer patients, there are around12 FDA approved medicines to control the cancer for the rest of your life. Each treatment will only work for so long before the cancer becomes resistant and the Oncologist is forced to abandon that therapy and move on to the next treatment. However, in 2020 there are over 1,300 active prostate cancer clinical research trials accruing. As I explain to my patients, if I had non-curable prostate cancer, I want the 12 FDA-approved treatments, but I also want an Oncologist who has knowledge and access to the 1,300 research options. The issue is not all Oncologists have access to many of the trials. They may say they do research but may only have a trial or two open that doesn't even fit your cancer situation. If your Oncologist is treating all cancer types he or she would have to keep up on over 21,000 clinical trials.....not possible.

  • No other Oncologist in the U.S. has access to as many innovative clinical trials for prostate cancer than Dr. Luke and his XCancer Omaha Research team. They often have patients on a trial first before any other center including all the major academic centers. As an example, using the newest most promising Radiopharmaceutical agents for prostate cancer. 3 centers in the entire U.S. were chosen: Memorial Sloan Kettering, Tulane University, and XCancer (Urology Cancer Center/GU Research, Omaha).

  • Furthermore, clinical trials are not the only way to improve survival and quality of life for patients. How an Oncologist manages the FDA-approved standard treatments matter immensely and varies widely. It is a little bit like a chess match. If I can get an extra 3-4 months out of 12 FDA-approved treatments for prostate cancer, that’s an extra 3 years of life and if another Oncologist is stopping those same treatments 3 months too soon, that's a 6-year swing in survival. Unfortunately, I see 2nd and 3rd opinions for patients from coast to coast, and frequently the FDA-approved standard treatments are mismanaged by another Oncologist or Urologist resulting in shortened life of the patient. As an example, many patients' treatments for prostate cancer are stopped when their PSA rises. Patients are educated with Dr. Luke that NO treatment should ever be stopped based on PSA alone. Patients can be on treatments for months to years longer in a setting of PSA rising with absolutely no progression of the cancer on scans. So in essence those Oncologists and Urologists are wasting life-saving treatments.

  • Often patients look at their Oncologist as someone that is primarily interested in giving medicines and may treat each patient like a number or a case and not like they would treat a member of their own family. Dr. Luke has had several family members and friends affected by cancer. He looks at each patient as if they were a family member. He isn't holding back any special treatments or ideas for someone else. Dr. Luke makes 3 promises to each patient for any treatment that he starts. He will only continue a treatment if:

    1) The treatment is working. Even if a patient is on a trial and the treatment stops working the treatment will be stopped immediately.

    2) The treatment is not hurting the patient. If a patient is experiencing mild side effects they will likely manage and continue treatment but if the patient experiences significant side effects the treatment will be modified or stopped.

    3) The treatment cannot break their bank. Dr. Luke's team works tirelessly to get free drug or work with very manageable payments. Patients on clinical trials typically pay nothing for their treatments.

    Prostate & Urologic cancers is all that Dr. Luke and his professional staff see. It is his passion and his calling. Every conference, they attend, every journal article they read or publish, and every meeting they participate in is focused only on these cancer types. Seeing over 400 men a month with prostate cancer from more than 40 states for over 20 years insures you as a patient are getting that wealth of experience and knowledge applied to your own case.

Not all board-certified Oncologists are the same. They have different training, different cancer interests, and different motivations. The majority of Oncologists spend their days treating ALL types of cancer.  In their typical clinic, they will treat patients with breast cancer, lung cancer, leukemias, lymphomas, colon cancer, prostate cancer, and more. The amount of knowledge that it takes to keep up with even one cancer type is expansive and keeping up with the latest information for all cancer types is borderline impossible.  Because of this vast mountain of information and rapidly changing treatment options, most oncologists can only provide standard-of-care treatments. That is good care, but it may be outdated and may not be your best care. In reality, it often limits your care.

Meet Dr. Luke Nordquist

Early in his career, Dr. Luke Nordquist realized the need for a cancer center dedicated solely to the treatment and research of Prostate & Urologic cancers. In 2010, Dr. Luke founded XCancer, formerly the Urology Cancer Center & GU Research Network in Omaha, NE. This cancer center has rapidly elevated to the level of an elite center of excellence for Prostate & Urologic Cancers. XCancer was the first cancer center in the U.S. to receive government NCQA recognition for its Patient-Centered Oncology Medical Home Program and the first cancer center in its region to receive QOPI certification from the American Society of Clinical Oncology for its excellence in quality cancer care.

Through its expert focus, efficiencies, and expanding network, XCancer & XCancer Omaha Research has become recognized globally by thought leaders, pharmaceutical companies, and patients as a leader in drug development through Phase 1-4 clinical trials. Dr. Luke has been the Principal Investigator on several hundred urologic cancer studies including several first-in-world treatments at XCancer. Dr. Luke serves as an expert on ASCO’s guidelines panel for Advanced Prostate Cancer.  

Dr. Luke started his career with a degree in Pharmacy followed by a Doctorate of Medicine, both from Creighton University. He completed a residency in Internal Medicine at the University of South Florida / H. Lee Moffitt Cancer Center in Tampa, FL. This was followed by a Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center & Medical College of Cornell in New York City. His clinical and research focus during his training was in prostate cancer and immune therapies.  

Dr. Luke has surfaced as a leader in the field of radiopharmaceuticals for the treatment of prostate cancer. He has conducted several clinical trials for agents such as Ra223 and Lu177. He has been chosen as one of three sites in the U.S. for two phase 1 studies utilizing Ac225 and Th227. He enrolled the first patient globally on the VISION study with Lu177 for advanced prostate cancer and accrued over 50 of the 800 total global patients for that study.

Dr. Luke is also the CEO of the XCancer Research Network. Using experience and tools developed and realized in the XCancer Omaha Research program, XCancer enables, oversees, and helps conduct clinical trials in community cancer centers across the U.S. This network provides much-needed access to potentially life-saving clinical trials to more cancer patients across the U.S. He realizes the vast research potential Community Cancer Centers hold, given they care for 80% of the U.S. cancer population but currently only enroll 2% of their patients on clinical trials. XCancer is currently working with community cancer centers. Many of these centers have the facilities, credentials, and ability to participate in radiopharmaceutical clinical trials.

Dr. Luke knows cancer patients are faced with many tough decisions and heavy burdens. He believes extensive patient education at an understandable level is at the center of excellent care and helping patients make their best decisions. Dr. Luke has served on the ASCO Government Relations Committee and is continually learning from and advocating for his patients both locally and nationally on the challenges they face and helping reduce their burdens.

Make Your Second Opinion An Expert Opinion